Aug 14 (Reuters) - Eli Lilly LLY.N has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs targeting cardiometabolic diseases and obesity, Superluminal said on Thursday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.